Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May 29;120(7):678-680.
doi: 10.1093/cvr/cvae057.

Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial

Christopher J Farina  1 , Michael H Davidson  2 , Prediman K Shah  3 , Charles Stark  1 , Wenqi Lu  1 , Cheerag Shirodaria  4 , Timothy Wright  1 , Charalambos A Antoniades  5 , Jan Nilsson  1   6 , Nehal N Mehta  7
Affiliations
Randomized Controlled Trial

Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial

Christopher J Farina et al. Cardiovasc Res. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P.K.S. and J.N. are signed as coinventors on patents assigned to Abcentra. M.H.D., P.K.S., T.W., and J.N. are members of the Abcentra Board of Directors. N.N.M. and C.S. are paid consultants to Abcentra. W.L. and C.J.F. are employees of Abcentra. C.A.A. is a Founder, shareholder and director of Cartisto Diagnostics, and declares relevant patents US10,695,023B2, PCT/GB2017/053262, GB2018/1818049.7, GR20180100490, and GR20180100510 from the University of Oxford, licenced to Caristo Diagnostics.

Figures

Figure 1
Figure 1
Study population and effects on coronary artery FAI score and CaRi-Heart Risk score in the whole-study population as well as in the high and low inflammation subgroups. (A) Flow chart of screening and (B) baseline clinical characteristics of the study population. (C) Change in FAI score and (D) CaRi-Heart® Risk score in the whole-study population as well as in the high and low inflammation subgroups. Changes in FAI and CaRi-Heart® Risk scores vs. baseline were analysed using a mixed effects linear model (PROC MIXED in SAS), including fixed effects for treatment and site with corresponding or appropriate baseline measures as a covariate. Differences in changes between treatment groups were analysed using Student’s t-test after confirming a normal distribution of the variable. P < 0.05 was considered statistically significant and significant differences are highlighted in red. (E) Representative images of changes in FAI score in response to orticumab treatment in the RCA and for placebo in the LAD. The colour scale visualizes the gradient from −190 Hounsfield Units (HU) representing the lowest degree of inflammation to 15 HU representing the highest level of inflammation. (F) Proposed mechanisms for the effect of orticumab on atherosclerosis. In the absence of orticumab, oxLDL binds to macrophage scavenger receptors (SR) in the arterial wall resulting in the release of pro-inflammatory cytokines promoting plaque inflammation and vulnerability. In the presence of orticumab, this process is inhibited resulting in reduced plaque inflammation and vulnerability. This in turn would be hypothesized to result in an inhibition of pericoronary adipocyte attenuation as detected by FAI score.
See this image and copyright information in PMC

References

    1. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, PROMINENT, REDUCE-IT, and STRENGTH Investigators . Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 2023;401:1293–1301. - PubMed
    1. Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 2021;42:113–131. - PubMed
    1. Steinberg D, Lewis A. Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062–1071. - PubMed
    1. Schiopu A, Bengtsson J, Soderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004;110:2047–2052. - PubMed
    1. Oikonomou EK, Antonopoulos AS, Schottlander D, Marwan M, Mathers C, Tomlins P, Siddique M, Kluner LV, Shirodaria C, Mavrogiannis MC, Thomas S, Fava A, Deanfield J, Channon KM, Neubauer S, Desai MY, Achenbach S, Antoniades C. Standardized measurement of coronary inflammation using cardiovascular computed tomography: integration in clinical care as a prognostic medical device. Cardiovasc Res 2021;117:2677–2690. - PubMed

Publication types

MeSH terms

Associated data